论文部分内容阅读
目的： 探讨肾癌及膀胱癌患者外周血中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）表达及意义． 方法： 采用ＥＬＩＳＡ 双抗体夹心法检测２４例膀胱癌、１５例肾癌，２０例正常对照外周血中ｓＩＬ－２Ｒ水平． 结果： 肿瘤患者ｓＩＬ－２Ｒ水平显著高于正常（Ｐ＜ ０．００１）． 虽然所有肿瘤患者ｓＩＬ－２Ｒ水平均升高，但其中肿瘤小、病理级别低者，ｓＩＬ－２Ｒ水平表现较低的趋势． 结论： 血清ｓＩＬ－２Ｒ能够反映机体抗肿瘤细胞免疫活性水平的高低；测定血清ｓＩＬ－２Ｒ水平可监测早期复发的肿瘤，并可作为肾癌、膀胱癌患者病期及预后判断的重要指标．
Objective: To investigate the expression of soluble interleukin-2 receptor (sIL-2R) in peripheral blood of patients with renal cell carcinoma and bladder cancer and its significance. Methods: The level of sIL-2R in peripheral blood of 24 cases of bladder cancer, 15 cases of renal cell carcinoma and 20 cases of normal controls was detected by ELISA double antibody sandwich method. Results: The level of sIL-2R in cancer patients was significantly higher than normal (P <0.001). Although sIL-2R levels were elevated in all cancer patients, the level of sIL-2R tended to be lower in those with small tumors and lower pathological grade. CONCLUSIONS: Serum sIL-2R can reflect the level of anti-tumor immune activity in the body. The level of serum sIL-2R can monitor the early recurrence of tumor, and can be used as an important index to judge the disease stage and prognosis of patients with renal cell carcinoma and bladder cancer.